Follow
Giuseppe Aprile
Giuseppe Aprile
Department of Oncology, Vicenza, Italy
Verified email at aulss8.veneto.it
Title
Cited by
Cited by
Year
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
The Lancet 376 (9742), 687-697, 2010
78762010
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
The Lancet 383 (9911), 31-39, 2014
23782014
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ...
The Lancet 392 (10142), 123-133, 2018
11442018
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease
K Qureshi, GA Abrams
World journal of gastroenterology: WJG 13 (26), 3540, 2007
890*2007
Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species
MG Perrelli, P Pagliaro, C Penna
World journal of cardiology 3 (6), 186, 2011
4502011
ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
Lancet 376 (9742), 687-697, 2010
3562010
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
3552019
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ...
Modern Pathology 28 (11), 1481-1491, 2015
2822015
Clinical advances in the development of novel VEGFR2 inhibitors
C Fontanella, E Ongaro, S Bolzonello, M Guardascione, G Fasola, ...
Annals of translational medicine 2 (12), 2014
2682014
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with …
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
2582020
New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury
M Cinausero, G Aprile, P Ermacora, D Basile, MG Vitale, V Fanotto, ...
Frontiers in pharmacology 8, 354, 2017
2532017
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised …
CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ...
The Lancet Oncology 20 (3), 420-435, 2019
2292019
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1952015
Peripheral blood markers identify risk of immune‐related toxicity in advanced non‐small cell lung cancer treated with immune‐checkpoint inhibitors
A Pavan, L Calvetti, A Dal Maso, I Attili, P Del Bianco, G Pasello, ...
The oncologist 24 (8), 1128-1136, 2019
1912019
Zolbetuximab plus mFOLFOX6 in patients with CLDN18. 2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction …
K Shitara, F Lordick, YJ Bang, P Enzinger, D Ilson, MA Shah, ...
The Lancet 401 (10389), 1655-1668, 2023
1822023
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ...
British journal of cancer 112 (12), 1921-1928, 2015
1762015
REGARD Trial Investigators Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
Lancet 383 (9911), 31-39, 2014
1412014
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
1372016
Role of mammography, ultrasound and large core biopsy in the diagnostic evaluation of papillary breast lesions
F Puglisi, C Zuiani, M Bazzocchi, F Valent, G Aprile, B Pertoldi, ...
Oncology 65 (4), 311-315, 2003
1372003
Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective …
A Russo, M Russano, T Franchina, MR Migliorino, G Aprile, G Mansueto, ...
Advances in therapy 37, 1145-1155, 2020
1352020
The system can't perform the operation now. Try again later.
Articles 1–20